Laromestrocel, an allogeneic preparation of culture-expanded mesenchymal stem cells, is being investigated for its potential to address inflammaging, vascular dysfunction, and abnormal skeletal muscle function—key contributors to frailty in older adults. Joshua Hare, chief scientific officer of Longeveron, emphasizes the therapeutic principle behind this approach, which aims to provide an off-the-shelf solution for treating aging frailty. The hypothesis stems from previous trials indicating that this cell therapy could enhance mobility in older populations suffering from frailty-related hypomobility.

In a phase 2b placebo-controlled, randomized, dose-finding study involving 143 participants aged 70-85 years with mild to moderate aging frailty (NCT03169231), the efficacy of laromestrocel was evaluated. Participants received either a placebo or a single dose of laromestrocel at varying concentrations (25 million, 50 million, 100 million, or 200 million cells). The primary endpoint was the 6-minute walk test (6MWT), a validated measure of hypomobility that closely correlates with frailty status. This study design aims to rigorously assess the therapeutic impact of laromestrocel on mobility, a critical factor in the quality of life for older adults.

The findings from this study could significantly influence the research paradigm surrounding frailty interventions. Should laromestrocel demonstrate efficacy in improving mobility, it may lead to the development of new therapeutic strategies targeting frailty and its underlying mechanisms. This could accelerate timelines for clinical applications of stem cell therapies in aging populations and shift focus towards regenerative approaches in managing age-related decline.

Source: nature.com